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Disorders of metal metabolism
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Abstract. Trace elements are chemical elements needed in minute amounts for normal physiology. Some of the physiologically
relevant trace elements include iodine, copper, iron, manganese, zinc, selenium, cobalt and molybdenum. Of these, some are
metals, and in particular, transition metals. The different electron shells of an atom carry different energy levels, with those
closest to the nucleus being lowest in energy. The number of electrons in the outermost shell determines the reactivity of such
an atom. The electron shells are divided in sub-shells, and in particular the third shell has s, p and d sub-shells. Transition
metals are strictly defined as elements whose atom has an incomplete d sub-shell. This incomplete d sub-shell makes them
prone to chemical reactions, particularly redox reactions. Transition metals of biologic importance include copper, iron,
manganese, cobalt and molybdenum. Zinc is not a transition metal, since it has a complete d sub-shell. Selenium, on the
other hand, is strictly speaking a nonmetal, although given its chemical properties between those of metals and nonmetals, it
is sometimes considered a metalloid. In this review, we summarize the current knowledge on the inborn errors of metal and
metalloid metabolism.
Keywords: Transition metals, Wilson disease, Menkes disease, MEDNIK syndrome, Huppke-Brendel syndrome, hemochro-
matosis, neurodegeneration with brain iron accumulation, acrodermatitis enteropathica, transient neonatal zinc deficiency,
spondylocheirodysplastic Ehlers-Danlos syndrome, Birk-Landau-Perez syndrome, hypermanganesemia with dystonia,
SLC39A8 deficiency, SEPSECS deficiency, SBP2 deficiency
1. Copper homeostasis
The human body contains approximately 100 mg of copper, of which 35 mg is in muscle, 20 mg in
brain, 10 mg in connective tissue, 5 mg in kidney, and 10 mg in blood [1, 2]. Copper absorption and
excretion are normally 1 to 5 mg daily (Table 1), with a net balance of zero. The alimentary system
generally achieves this balance through intestinal absorption and biliary excretion.
Between 80 and 95% of plasma copper is bound to ceruloplasmin, an alpha-glycoprotein with
amine oxidase and ferroxidase activities; the process of ceruloplasmin binding copper occurs in the
liver shortly after hepatic uptake of copper. Other copper-containing enzymes are listed in Table 2
and include tyrosine hydroxylase and dopamine hydroxylase, which produce neurotransmitters in the
central nervous system, and cytochrome c oxidase, critical for mitochondrial electron transport and
energy production. The major copper storage protein is metallothionein, which binds a variety of heavy
metals extremely tightly and whose promoter is very responsive to induction by heavy metals [3].
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Table 1
Copper balance and copper and ceruloplasmin values in health and disease
Normal Wilson Disease Menkes Disease
Copper dietary intake (mg/day) 5 5 5
Copper intestinal absorption (mg/day) 2 2 0.1–0.2
Copper biliary excretion (mg/day) 2 0.2–0.4 Not known
Copper urinary excretion (g/day) 15–60 100–1000 Increased
Copper balance 0 Positive Negative
Serum copper (mg/L) 0.75–1.45 0.19–0.63 <0.70
Serum ceruloplasmin (mg/L) 180–360 0–200 <50
Liver copper (g/g dry weight) 70–140 200–3000 10–20
Duodenal copper (g/g dry weight) 7–29 ? 50–80
Adapted from Danks DM [1] and Cullotta VC & Gitlin JD [2].
Table 2
Copper-containing enzymes
Enzyme Function Result of Deficiency
Ceruloplasmin Ferroxidase Anemia
Diamine oxidases Degrade histamine Increased histamine response
Superoxide dismutase Free radical detoxification Decreased protection against oxygen
free radicals
Cytochrome c oxidase Electron transport chain Decreased energy in muscle, neurons;
impaired myelination
Tyrosinase Melanin production in skin Reduced pigmentation
Dopamine--hydroxylase Dopamine production in neurons Reduced neurotransmitters
Catecholamine production Neurologic effects; temperature
instability pupillary constriction
Lysyl oxidase Cross-linking of collagen and elastin Arterial abnormalities; bladder
diverticulae; lax skin and joints
Peptidylglycine -aminating
monoxygenase
Removes carboxy-terminal glycine to
activate neuroendocrine peptides
Reduced activity of gastrin,
cholecystokinin, VIP, CRH, TRH,
calcitonin, vasopressin, MSH
Sulfhydryl oxidase Cross-linking of keratin Pili torti
Ascorbate oxidase Dehydroascorbate production Skeletal demineralization
Adapted from Danks DM [1] and Kaler SG [22].
1.1. Wilson disease
Wilson disease (hepatolenticular degeneration) is an inherited disorder that was first described by the
neurologist Samuel Alexander Kinnier Wilson [4]. The clinical manifestations of this disorder result
from an excessive accumulation of copper, first in the liver and then in the brain [5]. The disease has an
autosomal recessive mode of inheritance with a prevalence of 1 in 30000 live births and a prevalence
of the heterozygote-carrier state slightly higher than 1 in 100. With increased rates of consanguinity,
as occurs in certain isolated communities in Japan, Sardinia, and the Middle East, the frequency of
the gene for Wilson disease can be as high as 2% to 3%. Heterozygotes do not have any clinical
manifestations, although approximately 20% have low levels of ceruloplasmin and serum copper
[6, 7].
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The Wilson disease gene, ATP7B on chromosome 13q14.3, encodes a cation-transporting, P-type
adenosine triphosphatase (ATPase) [8–10]. The gene contains 21 exons. Its mutations number over
700 [11]; more than half of the disease-causing mutations are missense changes, the most common
being H1069Q [12]. In addition, the mutation R778L occurs in 30% of Asians with Wilson disease
[13–15]. There appears to be some genotype-phenotype correlation [16–20].
The ATP7B protein functions in the trans-Golgi region of hepatocytes, where it is responsible for
transporting copper into the secretory system. The Long Evans Cinnamon rat serves as a bone fide
model for human Wilson disease, since its mutations occur in the rat orthologue of ATP7B [21].
The basic defect in Wilson disease involves failure to excrete copper in the bile for elimination, and
failure to incorporate copper into its main circulating binding protein, ceruloplasmin. As a consequence,
copper builds up in the liver, exceeds the binding capacity of metallothionein, overflows into the
circulation bound to amino acids (especially cysteine), and deposits in susceptible tissues. Hence,
levels of hepatic copper are elevated and serum ceruloplasmin and copper levels are decreased.
1.1.1. Clinical characteristics
Although the biochemical defect that leads to the accumulation of copper in Wilson disease is
present at birth, clinical symptoms typically appear for the first time in older children, adolescents,
and young adults. Most patients present with hepatic [23, 24] or neurologic dysfunction; tremors and
ataxia reflect basal ganglia involvement, which can be seen as metal accumulation on imaging of
the brain [25, 26]. The brain MRI and MRS findings in Wilson disease have been reported [27, 28].
Electroencephalographic (EEG) changes are rarely helpful in diagnosis of neurologic cases.
Psychiatric, hematologic, renal, musculoskeletal, cardiac, ophthalmologic, endocrinologic, and
dermatologic presentations have all been described in Wilson disease, including acute hemolytic cri-
sis, joint symptoms, renal stones, renal tubular acidosis, pancreatic disease, cardiomyopathy, and
hypoparathyroidism [5]. Renal manifestations include elements of renal tubular malfunction; some
have the full picture of the Fanconi syndrome, including aminoaciduria, glycosuria, acidemia, rick-
ets, and poor growth. Copper overload has deleterious effects on the heart; many patients with Wilson
disease have electrocardiographic abnormalities, including conduction disturbances [29]. Anemia (nor-
mochromic) is not common except when there is hemolysis, but thrombocytopenia (50% of cases) and
neutropenia (30% of cases) are found frequently [30].
Up to 30% of patients with Wilson disease present with clinical, biochemical, and histologic features
similar to those of other forms of chronic hepatitis [23, 31]. Therefore, biochemical screening for Wilson
disease should be performed in all patients under the age of 40 years in whom the clinical or histologic
findings are consistent with chronic hepatitis and in whom autoimmune and viral disorders have been
eliminated as diagnoses. In some cases, the coagulopathy associated with the hepatic failure of Wilson
disease can interfere with obtaining a liver biopsy.
Patients with fulminant Wilson disease can be clinically indistinguishable from those with virus-
induced or drug-induced hepatic necrosis [24]. Viral illnesses may occur immediately preceding the
onset of acute hepatitis [32], raising the possibility that a patient’s hepatic decompensation may be
triggered by a viral infection. The sudden release of copper from the liver into the blood can cause
massive hemolysis, as copper is subsequently taken up by erythrocytes, causing oxidative damage
to cellular membranes. Acute hemolysis in Wilson disease is associated with hepatic damage, renal
insufficiency, and death [33].
The Kayser-Fleischer ring (Fig. 1) reflects the corneal accumulation of copper that has entered the
circulation from the liver. Kayser-Fleischer rings are golden-brown or greenish discolorations of the
limbic region of the cornea caused by copper deposition in the Descemet membrane; they occur in
patients with symptomatic Wilson disease, particularly those with neurologic manifestations [34]. The
presence of these rings, however, is not pathognomonic of Wilson disease, since they are occasionally
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Fig. 1. Appearance of Kayser-Fleischer ring in Wilson disease. Dark pigment at periphery of the cornea is due to deposition
of copper.
observed in patients with other cholestatic hepatic diseases. Conversely, the rings are absent in many
patients with Wilson disease, even those with fulminant hepatitis [24]. Sunflower cataracts occur in a
smaller proportion of cases (15%–20%); both of these ocular signs improve with effective chelation
therapy [1].
1.1.2. Diagnosis
The diagnosis of Wilson disease requires a clinical suspicion combined with laboratory evidence
[35]. Clinical findings may include hepatic, neurological, or renal abnormalities, and possibly Kayser-
Fleischer rings. Laboratory findings generally include elevated urinary copper levels [24] and low serum
copper and ceruloplasmin. However, in 5–15% of Wilson disease patients, the serum ceruloplasmin
values may be normal. In these cases, the ceruloplasmin, measured as the apoprotein, may not bind
copper appropriately, or may be increased because of hepatic inflammation, since ceruloplasmin is an
acute phase reactant [23, 31]. Liver copper is usually elevated in Wilson disease, but hepatic copper
values may be normal because of the massive release of hepatic copper stores.
One noninvasive and reasonably definitive test is measurement of urinary copper after a penicillamine
challenge [36]. Urinary excretion of 1000 to 2000 mg copper within 24 hours after oral administration of
1 g penicillamine is diagnostic [6]. Alternatively, molecular diagnostics can be performed for mutations
in the ATP7B gene [5].
Wilson disease cannot be ruled out on the basis of any single laboratory test.
1.1.3. Pathology
The pathologic effects on the liver, kidneys, and brain are directly related to the accumulation
of copper ions. Four pathophysiologic phases are acute hepatitis, fulminant hepatitis, chronic active
hepatitis, and cirrhosis.
In the precirrhotic stage, the changes resemble a chronic, active hepatitis with focal necrosis, scat-
tered acidophilic bodies, and moderate to marked steatosis [37]. Glycogenated nuclei in periportal
hepatocytes are a typical finding. Kupffer cells are hypertrophied and may contain hemosiderin. Sub-
massive or massive hepatocellular necrosis may occur; the clinical and biochemical findings in such
cases may resemble those of chronic active hepatitis [4, 23, 37]. In later stages, periportal fibrosis,
portal inflammation (Fig. 2), and finally cirrhosis occur. The presence of copper may not be cytochem-
ically demonstrable in the precirrhotic stage. In young, asymptomatic patients, the copper is diffusely
distributed in the cytoplasm but later accumulates in lysosomes [37]. Rhodamine and rubeanic acid
stains are specific to detect the presence of copper (Fig. 3) [23]. Copper-associated protein can be
stained with orcein or aldehyde fuchsin [38, 39]. Cirrhosis may be micronodular or macronodular
(Fig. 4), or it may be mixed. Variable degrees of bile duct proliferation and inflammation have been
reported [40]. Mallory bodies are frequently present in periportal hepatocytes [40, 41]. Single-cell
necrosis and submassive or massive coagulative necrosis [40] may be seen. Tissue copper deposition,
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Fig. 2. Wilson disease. (A) Microscopic section of liver in inflammatory reaction in the portal area. The hepatocytes contain
copper pigment. (B) High-power view showing Mallory body (arrow).
Fig. 3. Microscopic section of liver in Wilson disease showing copper pigmentation of hepatocytes stained with Rhodamine
stain.
when present, is generally confined to the periportal zone in early stages of the disease but may be
diffusely distributed by the time cirrhosis has developed [32, 40, 42].
Liver copper, typically measured by Inductively Coupled Plasma Optical Emission Spectroscopy
(ICP-OES) or ICP-Mass Spectrometry (ICP-MS) may detect 10 to 35 g of copper per gram of dry
liver weight in normal individuals. More than 250 g/g is diagnostic of Wilson disease, although lower
cut-off values have been proposed [43–45].
Extensive sampling may be necessary to confirm the diagnosis of Wilson disease. Furthermore,
increased hepatic copper, with levels as high as 250 g/g of dry weight, is seen in diseases other than
Wilson disease, including chronic cholestatic diseases such as primary biliary cirrhosis and primary
sclerosing cholangitis, Indian childhood cirrhosis, and copper-associated cirrhosis [42, 44].
On histologic examination, a negative copper stain of the liver does not rule out a diagnosis of
Wilson disease [42], particularly during the initial stages of copper accumulation when the metal
is distributed diffusely throughout the cytoplasm of the hepatocyte and may be undetectable with
routine staining techniques [32, 38, 46, 47]. It is imperative to establish the correct diagnosis, since
the morbidity and mortality rates are very high among untreated persons [23], and chelation therapy
or liver transplantation frequently results in long-term survival.
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Fig. 4. Gross appearance of cirrhotic liver in Wilson disease.
Fig. 5. Wilson disease. Coronal section of brain showing small cystic cavitation and light brown discoloration in the basal
ganglia, particularly in the putamen.
The pathologic changes in the brain (Fig. 5) are characterized by rarefactive spongy change pro-
gressing to cavitary necrosis with microcysts primarily in the putamen and rarely in neocortical layers
V and VI. Severe white matter degeneration and neuronal loss may be seen. Pathological types of
astroglia can be seen in the form of Alzheimer type I cells (mainly in the putamen) and Alzheimer
type II cells (distributed diffusely). Opalski cells, round, large cells (>35 m) with a small nucleus and
finely granular, eosinophilic cytoplasm, are characteristic of Wilson disease and are mainly found in
the putamen [48, 49]. The brain has high concentrations of copper.
The ultrastructural changes are pathognomonic (Fig. 6) [50]. The mitochondria show marked pleo-
morphism: the cristae are wide and microcysts form at the tips of the cristae. Copper deposits are
extremely electron-dense.
The histologic differential diagnosis of Wilson disease includes diabetes mellitus, ethanol abuse, viral
or autoimmune hepatitis, 1-antitrypsin deficiency, and rare idiosyncratic drug reactions, all of which
can produce findings similar to those of Wilson disease. Overdoses of drugs such as acetaminophen
[40] and ingestion of toxins such as carbon tetrachloride and tannic acid [36] may cause submassive
necrosis with steatosis, as in Wilson disease.
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Fig. 6. Electron micrograph of hepatocyte in Wilson disease. The mitochondria vary in size and shape, with dilated and
microcystic cristae. (Courtesy Dr. Roma Chandra.)
1.1.4. Treatment
Patients with acute hepatic failure from Wilson disease tend to be young and have a fulminant
clinical course, with survival requiring acute management followed rapidly by liver transplantation. A
prognosis index for Wilson disease patients with fulminant hepatitis is based on the serum bilirubin,
aspartate aminotransferase, and prothrombin time [50, 51]. Hemolysis and renal insufficiency are grave
prognostic signs [24]. Hepatic transplantation for Wilson disease is associated with a survival rate of
approximately 72 to 79% at 5 years [52–54]. All transplant recipients have a complete reversal of the
underlying defects in copper metabolism, and many have improvement in symptoms and signs [25].
Treatment of chronic or subacute Wilson disease involves lifelong chelation therapy with penicil-
lamine [55] or trientine hydrochloride [56, 57]. Chelators may decrease pyridoxine, which should be
added. An alternative approach to chelation is the administration of zinc, which induces metalloth-
ionein in the gastrointestinal mucosa. Dietary copper displaces the zinc, and subsequent sloughing
of mucosal cells results in decreased copper absorption. This therapy is not as effective as chelation
[58], and should be considered complementary to chelation therapy, except in children with mild liver
disease [59].
During these medical therapies, serum copper levels should be monitored, since therapy may be
inadequate or may result in copper deficiency [60–62]. If treatment regimens prove inadequate, liver
transplantation should be considered [63, 64]. Gene therapy has been discussed for Wilson disease
[65].
1.2. Menkes disease
In 1962, John Menkes and colleagues from Columbia University in New York described five males
from a single family with progressive neurologic deterioration after a few months of life, failure
to thrive, and peculiar hair [66]. David Danks in Melbourne noticed that the hair of children with
this condition was similar to the wool produced by sheep that grazed on grass from copper-depleted
soil in Australia, where wool remained an important industry [67]. This led him to evaluate copper
metabolism in 7 patients with Menkes disease, all of whom were found to have decreased serum copper
and ceruplasmin levels [68]. Inherited as an X-linked recessive disorder of copper metabolism, Menkes
disease is characterized by a defect in the transport and incorporation of copper into copper-containing
enzymes [22, 66, 67, 69]. As a result, serum levels of copper and ceruloplasmin are low in affected
male infants [67, 69], and all copper-containing enzymes (Table 2) have impaired activity. Copper
levels are low in most tissues except the kidney and intestinal mucosa, with levels in liver remarkably
decreased (Table 1) [67].
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The incidence of Menkes disease is approximately 1 in 250,000 [69]. The Menkes disease gene,
ATP7A, resides on chromosome Xq13.3 and contains 23 exons [10]. A wide variety of mutations
have been described; most are private, with some genotype-phenotype correlation [70]. As for most
X-linked disorders, one-third of cases are predicted to be new mutations. Full manifestation of the
disease has been described in 23 girls [71–81].
The Menkes disease protein, ATP7A, is 55% identical to the Wilson disease protein, ATP7B [2].
ATP7A resides in the trans-Golgi network [82] and transports copper into the secretory vesicle system
for incorporation into copper-containing enzymes [2]. The basic defect in Menkes disease prevents
the transport of copper out of gastrointestinal mucosal cells and into the circulation; consequently,
intestinal mucosal cells store large amounts of copper. Copper egress from cultured fibroblasts is
impaired in Menkes disease [1, 2]. The mottled mouse is a model for Menkes disease [83].
1.2.1. Clinical characteristics
The severity of Menkes disease is quite variable [84]; the clinical manifestations result from defi-
ciency of different copper enzymes [67, 69]. Tyrosinase deficiency causes hypopigmentation of hair
and skin pallor. Lysyl oxidase deficiency results in frayed and split arterial intima due to defective
elastin and collagen cross-linking. Deficiency of cytochrome c oxidase causes hypothermia and ascor-
bate oxidase deficiency causes skeletal demineralization. Dopamine -hydroxylase deficiency results
in decreased catecholamine synthesis.
Infants with Menkes disease have a sparse, steel wool appearance to their hair, which is coarse and
brittle; this phenomenon is called pili torti (Fig. 7). The hair becomes tangled, lusterless, and grayish or
ivory-colored, with a stubble of broken hairs palpable over the occiput and temporal regions where the
hair rubs on sheets. Microscopic examination of the hair will reveal the pili torti [1]. Menkes disease
infants have pudgy cheeks, skeletal changes [85] including wormian bones, metaphyseal widening
-particularly of the ribs and femora- and lateral spurs, progressive cerebral deterioration with seizures,
and widespread arterial elongation and tortuosity [67, 69]. There can be metaphyseal fractures mimick-
ing the classic metaphyseal lesion from child abuse. This, in combination with subdural hematomas,
can lead to confusion with non-accidental trauma [86, 87].
Many of the effects of Menkes disease are established in utero. Premature delivery is very frequent,
as are neonatal hypothermia and hyperbilirubinemia. Hypothermia may also occur in older babies. In
the neonatal period, the child’s growth and appearance can be normal, with fine hair and sometimes
an unusual facies. Some Menkes disease babies, however, show early symptoms. By about 3 months
of age, most affected infants develop flagrant symptoms of developmental delay, loss of early devel-
opmental skills, and seizures. Cerebral degeneration then dominates the clinical picture, with vascular
Fig. 7. Menkes syndrome child with typical coarse kinky hair.
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Table 3
Major clinicopathologic findings in menkes disease and related phenotypes
Craniofacial Coarse hair, with pili torti
Wormian bones, especially within lambdoidal sutures
Occipital exostoses (in the occipital horn variant and some
mild phenotypes)





Rib fractures (typical in classic Menkes)
Urinary tract Massive bladder diverticula
Skin and joints Generalized laxity
Vasculature Generalized tortuosity/ectasia
Adapted from Kaler SG [22].
complications, particularly subdural hematomas [1, 69]. Progressive neurologic degeneration leads to
death in infancy. The clinical and laboratory manifestations of classic Menkes disease are shown in
Table 3.
About half of obligate heterozygotes for Menkes disease can be identified by studies of copper
incorporation into fibroblasts obtained from a skin biopsy [88] or by examination of hair for pili torti
[89]. Patchy suntanning can occur in white heterozygotes. Finding elevated placental copper levels
seems to be a particularly good method of diagnosing heterozygotes when females are born into
affected families [90].
1.2.2. Diagnosis
As for Wilson disease, the diagnosis of Menkes disease relies upon a combination of clinical and
laboratory findings [69, 91]. Clinical diagnostic tests are often characteristic [67]. Electroencephalo-
grams are usually moderately to severely abnormal [92] although normal tracings have been recorded
in some classically affected individuals [93]. Brain MRI findings typically include white matter abnor-
malities reflecting impaired myelination, tortuosity of cerebral blood vessels, and/or diffuse atrophy
with ventriculomegaly [94]. Subdural hematomas are common in infants, and cerebrovascular acci-
dents can occur in patients who survive longer. Cystography or pelvic ultrasound reveals diverticula of
the urinary bladder in nearly every patient. Radiographs often disclose abnormalities of bone formation
in the skull (wormian bones), long bones (metaphyseal spurring), and ribs (anterior flaring, multiple
fractures) [95, 96].
Laboratory findings include low levels of serum copper and ceruloplasmin (Table 1). Serum copper
and ceruloplasmin are unreliable as diagnostic markers during the first several weeks of life, since chil-
dren under age 6 months normally have low serum levels of both markers [69]. Instead, one should rely
upon concentrations of neurochemicals. Partial deficiency of dopamine hydroxylase, a critical enzyme
in the catecholamine biosynthetic pathway, is responsible for a distinctively abnormal plasma and cere-
brospinal fluid neurochemical pattern in Menkes patients [97, 98]. The ratio of a proximal compound in
the pathway, dihydroxyphenylalanine (DOPA) –or dopamine metabolite dihydroxyphenylacetic acid
(DOPAC)- to a distal metabolite dihydroxyphenylglycol (DHPG), provides a better index of DBH
deficiency in Menkes patients than norepinephrine levels alone, as does the ratio of dopamine to nore-
pinephrine [22, 99]. Definitive diagnosis can also be made based upon mutation analysis of ATP7A [69].
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Fig. 8. Section of cerebral white matter in Menkes disease showing telangiectatic capillary.
1.2.3. Pathology
Pathologic changes involve the cardiovascular system. Developmental and degenerative changes are
seen in the arteries with elongation, aneurysmal dilations, telangiectasia (Fig. 8), rupture, stenoses, and
areas of intimal proliferation and thrombosis. Extreme fragmentation, disruption, and reduplication
of the internal elastic lamina are seen microscopically (Fig. 9), especially in the large arteries [100].
Intimal changes are also seen. Aorta and skin ultrastructural changes suggest defective formation rather
than disruption of tissue elastic fibers [101].
There is widespread neuronal destruction in the cerebral cortex and the cerebellum, as well
as associated gliosis [102–104]. Cerebellum changes are severe with neuronal loss in the gran-
ular cell layer and molecular layer. There is proliferation of the Bergmann glia [71, 105].
Many Purkinje cells are lost, and those that remain show several abnormalities: 1) heterotopia,
or displacement into the granular layer; 2) somal sprouts, or short, radial dendrites emanating
directly from the soma of the Purkinje cell; 3) cacti, or enlarged, swollen dendrites; 4) abnor-
mal arborization of dendrites, with a weeping willow configuration (downward extension), or a
Medusa head formation; 5) focal axonal swellings, either fusiform (torpedoes) or round (retrac-
tion bulbs); 6) confronting cisternae complexes, seen ultrastructurally as laminated structures with
alternating 5–83 nm clear zones and 30 nm dense zones; enlarged, swollen mitochondria with tubule-
vesiculated cristae and occasional glycogen accumulation, also seen on electron microscopy [66, 71,
105–110].
Changes in the skeletal muscle (glycogen accumulation, mitochondrial disorganization, “ragged red
fibers”) and in the iris and retina have been described, including progressive degeneration of ganglion
cells, leading to loss of nerve fibers and optic atrophy, abnormal retinal pigment with small and irregular
melanin granules, and abnormal elastica in Bruch’s membrane [111].
By formaldehyde-induced fluorescence for the identification of catecholamines, peculiar torpedo-
like swellings of catecholamine-containing axons are seen in the peripheral nerve tracts, as are
reduced numbers of adrenogenic fibers in the mid-forebrain [100, 112]. Deficient cytochrome
c oxidase activity seems likely to be a major factor in the devastating brain damage asso-
ciated with classic Menkes disease. Neuropathologic changes in Menkes patients are similar
to those found in individuals with Leigh disease (subacute necrotizing encephalomyelopathy)
in whom cytochrome c oxidase deficiency is caused by complex IV respiratory chain defects
[113].
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Fig. 9. Menkes disease. (A) Microscopic section of the aorta showing disruption and piling up of elastic fibrils of internal
elastic lamella. (B) Fluorescence photomicrograph of longitudinal section of peripheral nerve. Note torpedo-like swelling
of intense fluorescence-positive axon. Inset shows cross section of peripheral nerve with nonspecific fluorescence of myelin
sheath (formaldehyde-induced fluorescence). (Courtesy of Dr. Hideo Uno.)
1.2.4. Treatment
There is no effective treatment for Menkes disease, although some benefit may accrue following
treatment with copper histidinate started soon after birth, particularly if there is residual ATP7A activity
[91, 114].
1.3. Occipital horn syndrome
Occipital horn syndrome (OHS) is a mild allelic variant of Menkes disease [115, 116] in which
connective tissue features (lax skin, loose joints, hernias, bladder diverticula, abnormally shaped bones,
and vascular tortuosity) predominate [115]. Survival into adult life is usual [1]. OHS patients have
mutations in ATP7A. The disease is named for the pathognomonic wedge-shaped calcification that
forms within the trapezium and sternocleidomastoid muscles at their attachment to the occipital bone
in affected individuals. Intellect is in the low-normal to mildly impaired range. Additionally, some
patients have signs of autonomic dysfunction, such as syncope and episodic diarrhea that are highly
suggestive of DBH deficiency [117]. In typical OHS, neurologic findings are otherwise essentially
normal, whereas other clinical variants have been described that fall between the classic Menkes
and occipital horn syndromes with respect to neurologic phenotype [118, 119]. Definitive diagnosis
can be made based upon mutation analysis of ATP7A. Plasma copper and ceruloplasmin levels are
in the low-normal range. Copper egress in cultured fibroblasts is impaired to the same degree as in
classic Menkes disease. Treatment with copper histidinate gives results similar to those for Menkes
disease [91].
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1.4. X-linked distal hereditary motor neuropathy
This is the third, and mildest, condition caused by mutations in ATP7A. It is characterized by
an adult-onset, progressive distal muscle weakness of hands and feet, with absent or minimal sen-
sory involvement, and with normal serum copper, ceruloplasmin and neurochemical ratios [69, 120].
Sural nerve biopsies in one patient revealed no abnormalities [121] Two unique mutations, p.T994I
and p.P1386S, have been associated with this phenotype [122]. Normally, ATP7A recycles continu-
ously between the Golgi and the plasma membrane, while the two aforementioned mutations result in
preferential accumulation in the plasma membrane [120].
1.5. MEDNIK syndrome
The name MEDNIK syndrome is an acronym for some of the main clinical features of the disease,
including Mental retardation, Enteropathy (diarrhea), Deafness (in the form of sensorineural hearing
loss), peripheral Neuropathy, Ichthyosis, and Keratodermia [123]. Other features include hepatopathy
with elevated transminases and cholestasis, decreased serum ceruplasmin and copper although with
increased non-ceruloplasmin bound copper, increased urine copper excretion, and increased liver cop-
per concentration [123]. There is also a mild increase in plasma very long-chain fatty acid levels, as
well as bilateral T2-weighted hyperintensities of the basal ganglia. Most reported patients have been
from the Kamouraska municipality of Quebec [124]. It is caused by mutations in AP1S1, encoding
the σ1A subunit of the adaptor protein complex AP-1 [125]. Normally, the copper ATPases recycle
from the trans-Golgi network to the plasma membrane, depending on the intracellular concentrations
of copper. At basal concentration, the ATPases transfer copper to cuproenzymes in the Golgi, while
at increased copper concentrations, they translocate to the plasma membrane in order to contribute to
copper excess efflux. This intracellular trafficking is dependant on adaptor proteins, and thus mutations
in AP1S1 disrupt the cycle [123]. Treatment with zinc acetate might improve cholestasis and intel-
lectual development [123]. Liver biopsies revealed intrahepatic cholestasis in one patient, and fibrosis
and/or cirrhosis in other two [123]. A skin biopsy from what was likely the first patient reported with
the condition revealed prominent epidermal hyperkeratosis with mild inflammatory infiltrate around
dermal blood vessels. A muscle biopsy from the same patient showed focal infiltration of lymphocytes
around isolated muscle fibers [126].
1.6. Huppke-Brendel syndrome
Huppke, Brendel and colleagues described five patients from four independent families with devel-
opmental delay, congenital cataracts, nystagmus, hearing loss, white matter hypomyelination, cerebral
and cerebellar atrophy, early lethality, and low serum copper and ceruloplasmin levels [127]. Urine
copper was normal. Horváth et al. had previously reported one of those patients, whose muscle biopsies
revealed a dilated sarcoplasmic reticulum as the most conspicuous finding [128]. Huppke-Brendel syn-
drome is caused by mutations in the SLC33A1 gene, encoding for a transporter (AT-1) that translocates
acetyl-CoA into the ER lumen [127]. It is postulated that decreased acetylation of ceruloplasmin leads
to its decreased secretion, and the low serum copper is just a secondary phenomenon, as ceruloplasmin
carries 95% of serum copper [127].
2. Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation (NBIA) comprises a group of various inherited
neurodegenerative disorders characterized by the excessive accumulation of iron in the basal ganglia,
and sometimes elsewhere, within the central nervous system. The neuropathology of NBIA is char-
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acterized by iron accumulation, axonal spheroids, and variable findings of tau-positive neurofibrillary
tangles (NFTs) or -synuclein-positive Lewy bodies [129]. Ferrous iron is stained by Turnbull’s blue,
while ferric iron is stained by Prussian blue (also known as Berlin blue, or Perls stain). A summary of
the different subtypes of NBIA can be found in Table 4.
2.1. Pantothenate kinase-associated neurodegeneration (PKAN)
The first case of NBIA was described by neuropathologists Julius Hallervorden and Hugo Spatz in
1922 [133]. Five sisters (including a pair of twins) presented with dystonia, dysarthria and progressive
cognitive impairment starting between the ages of 7 and 9 years, ending with death between 16 to
27 years old. The neuropathology revealed abnormal accumulation of iron in the globus pallidus and
substantia nigra [134]. For a while the disease was known as Hallervorden-Spatz syndrome, but given
their involvement with the Nazi regime, the use of this eponym has decreased significantly over the
last couple of decades [135]. PKAN represents 35 to 50% of all cases of NBIA [130]. Classic PKAN
presents in the first decade of life (at a mean age of 3.4 years) with progressive gait disturbances due
to the presence of dystonia and rigidity [136]. Loss of ambulation occurs 10 to 15 years after the onset
of the disease. The rate of cognitive impairment might be overestimated given the severity of motor
disability over time [136]. Two thirds of patients have pigmentary retinal degeneration. One quarter of
patients have atypical PKAN, presenting after the age of 10 years (at a mean age of 13.6 years), with loss
of ambulation 15 to 40 years later [136]. HARP syndrome (Hypoprebetalipoproteinemia, Acanthocy-
tosis, Retinitis pigmentosa, and Pallidal degeneration) is part of the disease spectrum. Iron is primarily
deposited in the form of coarse hemosiderin granules around blood vessels, in the cytoplasm of astro-
cytes (not in microglia or oligodendroglia), and less prominently so in the cytoplasm of neurons, and in
the neuropil (“iron dust”) [137]. Neuroaxonal spheroids can be seen in the globus pallidus, corpus cal-
losum and subcortical white matter. Degenerating neurons stain strongly for ubiquitin, and weakly for
tau [137]. Pantothenate kinase is the first enzyme in the biosynthesis of coenzyme A from pantothenate
(vitamin B5). It phosphorylates pantothenate into 4-phosphopantothenate. Pantethine supplementation
has been proposed as a treatment for PKAN, since it bypasses the metabolic defect [138].
2.2. PLA2G6-associated neurodegeneration (PLAN)
This disease accounts for 20% of all NBIA cases [130]. It can be classified into three overlapping
phenotypes, from more to less severe: infantile neuroaxonal dystrophy (INAD, presenting before age 3
years), atypical neuroaxonal dystrophy (with onset before age 20 years), and PLA2G6-related dystonia-
parkinsonism [139]. INAD was first described by Seitelberger in 1952 [140], thus its old nomenclature
of Seitelberger disease. What was originally described as Karak syndrome [141] is now known to be
atypical NAD. In neuroaxonal dystrophy, developmental regression is the rule. Neuropathologically,
the disease is characterized by pronounced demyelination associated with the presence of spheroids
in the axons of the white matter of the cerebral hemispheres (Fig. 10) [142]. Ultrastructure shows
amorphous electron-dense material in unmyelinated axons (Fig. 11). Diagnosis is made by pathologic
examination of brain, peripheral nerve, conjunctiva, skin, or rectal biopsy. The characteristic axonal
swellings are detected by histochemical and ultrastructural techniques [143–148]. Macroscopically,
the brain of affected infants shows atrophy of the cerebral hemispheres with ventricular dilation and
cerebellar atrophy. Histologically, axonal spheroids are seen in the grey matter of the nervous system
with degeneration of corticospinal and spinobulbar tracts associated with reactive astrocytosis. An
infant with cerebellar localization has been described [149]. Alpha-synuclein-positive Lewy bodies
and Lewy neurites have been described in all forms of the disease, mainly in the substantia nigra
and neocortex [129, 150], while early-onset cases tend to have tau-positive neurofibrillary tangles and
neuropil threads [150]. Iron deposition is inconsistent, seen in less then 50% of patients [151].
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Fig. 10. Neuroaxonal leukodystrophy. There are axonal spheroids in white matter associated with myelin degeneration.
Fig. 11. Infantile neuroaxonal dystrophy. A portion of one of the unmyelinated axons (asterisk) in this conjuctival perivascular
nerve is distended by an accumulation of tubulo-membranous structures, degenerate organelles, and amorphous electron-dense
materials. With these, distinctive axonal “spheroids” become more condensed and display characteristic clefts. (Courtesy of
Dr. Gary Mireau.)
2.3. Mitochondrial membrane protein-associated neurodegeneration (MPAN)
The disease accounts for 6–10% of all cases of NBIA [130]. Gait impairment is the most common
presenting feature, dystonia and dysarthria are common during the course of the disease, and progres-
sive cognitive deterioration is the rule [152]. Disease progression is typically slow, with survival well
into adulthood, distinguishing it from other types of NBIA [152]. Widespread Lewy bodies and Lewy
neurites are found in basal ganglia, substantia nigra and neocortex, with Lewy bodies being about 6
times more abundant in MPAN than in PLAN [129, 153]. Spheroids can be found both in the central
and peripheral nervous systems, just as in PLAN [153]. One patient showed decreased estimated iron
content in the substantia nigra, with stable content in the globus pallidus after months of treatment
with deferiprone [154].
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2.4. Beta-propeller protein-associated neurodegeneration (BPAN)
This is the only X-linked NBIA, accounting for 1–2% of all cases [130]. BPAN was previously
referred to as “Static Encephalopathy of childhood with NeuroDegeneration in Adulthood”, or SENDA,
since it presents with static developmental delay during childhood, with progressive parkinsonism, dys-
tonia and dementia in early adulthood [155]. Neuropathology reveals numerous large axonal spheroids
primarily in the globus pallidum and substantia nigra, axonal torpedoes in the cerebellar granular cell
layer [156], and extensive deposition of tau-positive neurofibrillary tangles, pre-tangles and neuropil
threads [157].
The rest of the causes of NBIA account for less than 1% of cases each [158].
2.5. COASY protein-associated neurodegeneration (CoPAN)
Coenzyme A synthase (COASY) is a bifunctional enzyme that performs the last two steps in coen-
zyme A synthesis. These include the conversion of 4’-phosphopantetheine into dephospho-coenzyme
A by phosphopantetheine adenylyltransferase (PPAT), and the dephosphorylation of dephospho-
coenzyme A into the final product, coenzyme A, by dephospho-CoA kinase (DPCK) [159]. This
is the second inborn error of CoA biosynthesis to be associated with NBIA, although the mechanism
by which coenzyme A deficiency leads to altered iron metabolism remains unknown. There are two
other enzymes participating in the biosynthesis of CoA that have not yet been associated with human
disease. The disease has been reported in two patients presenting with spasticity before the age of
3 years, followed by progressive dystonia, dysarthria and parkinsonism [160]. Neuropathology is not
available.
2.6. Fatty acid hydroxylase-associated neurodegeneration (FAHN)
The deficient enzyme normally -hydroxylates myelin galactolipids, galactosylceramide, and sul-
fatides [161]. The disease has been reported in less than 30 individuals from different ancestry. It can
present as a dysmyelinating leukodystrophy and spasticity with or without dystonia, or as spastic para-
plegia 35 [162]. Spasticity is a universal finding, dystonia, ataxia, cognitive decline and optic atrophy
are seen in the majority of patients, and seizures are common [162]. The disease typically presents
between the ages of 3 and 11 years [162]. The finding of a thin corpus callosum in the setting of NBIA
should raise concern for FAHN [132]. Neuropathology of the central nervous system is not available.
Sural nerve biopsy in one patient showed mild decrease in myelinated fibers [161], while sural nerve,
skin and muscle biopsies in another patient were normal [163], and muscle biopsy in one more patient
showed signs of denervation and reinnervation [164]. Although not required for the diagnosis, a bone
marrow biopsy may reveal granular histiocytes [162].
2.7. Kufor-Rakeb syndrome
The disease was initially described in the village of Kufor-Rakeb, in Jordan, in 1994 [165]. It is
characterized by parkinsonism starting in adolescence of early adulthood, oculomotor abnormalities
such as supranuclear gaze palsy or oculogyric crisis, cognitive involvement including dementia and
visual hallucinations, and a characteristic facial-faucial-finger mini-myoclonus [166]. As in PLAN,
iron accumulation is inconsistent [151]. Membrane-bound electron-dense lamellated inclusions have
been found in fibrocytes, endothelial cells, and macrophages from skin biopsies, and intermyofibril-
lar, subsarcolemmal and endomysial regions from muscle biopsies [167]. Another patient had a sural
nerve biopsy showing reduced myelinated fiber density, axonal degeneration, and numerous cytoplas-
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mic inclusions in endoneurium, perineurium and vascular smooth muscle cells. Ultrastructurally, these
inclusions are membrane-bound, electron dense, occasionally folded, and irregular [168]. Neuropathol-
ogy in one patient with mutations in ATP13A2 revealed extensive neuronal and glial liposfuscinosis,
with sparing of the white matter [169].
2.8. Woodhouse-Sakati syndrome
The disease, first described by Woodhouse and Sakati in 1983, is characterized by diabetes mellitus,
alopecia, hypogonadism, deafness, dystonia, and intellectual disability [170]. There is often no iron
accumulation, as in PLAN and Kufor-Rakeb syndrome [151]. Neuropathology is not available.
2.9. Neuroferritinopathy
It is the only NBIA with autosomal dominant inheritance. This adult-onset condition presents with
chorea in half of patients and dystonia in 42.5%, while over the course of the disease dysarthria
develops in 77.5% of patients and orolingual dyskinesia in 65% [171]. Serum ferritin is low (<20 g/L)
in most males and post-menopausal women, but it is normal in pre-menopausal females [172]. The
characteristic finding is that of swollen, distorted, vacuolated nuclei in neurons and glia, primarily in
the putamen [129, 173]. Hepatocytes also contain vacuolated nuclei that stain positively for iron [173].
Ubiquitin- and tau-positive neuroaxonal spheroids can be seen in the putamen, although they are not
prominent [129].
2.10. Aceruloplasminemia
The disease was first described by Miyajima in 1987 [174]. Ceruloplasmin is synthesized in hep-
atocytes and secreted into the serum with 6 atoms of copper incorporated during biosynthesis [175].
Ceruloplasmin is an acute-phase reactant, and the serum concentration increases during infection,
inflammation, and trauma largely due to effects on hepatic ceruloplasmin gene expression [176]. The
ceruloplasmin gene is on chromosome 3q23-25, and abundant, tissue-specific expression of this gene
is found in the liver [177].
Aceruloplasminemia is an extremely rare autosomal recessive disorder of iron metabolism character-
ized by diabetes, retinal degeneration, and neurologic symptoms [178]. Affected patients have marked
parenchymal iron accumulation in conjunction with an absence of circulating serum ceruloplasmin,
and molecular genetic analysis reveals inherited mutations in the ceruloplasmin gene [2, 177].
Ceruloplasmin is essential for the release of iron from reticuloendothelial storage sites. Specifically,
the ferroxidase activity of ceruloplasmin is required to oxidize ferrous to ferric iron for incorporation
into transferrin and subsequent transport out of cells [179]. Hence, in aceruloplasminemia, ferrous
iron accumulates in the plasma and is rapidly removed from the circulation by the liver and other
tissues [180]. There is a marked increase in iron in both hepatocytes and reticuloendothelial cells
[181]. The serum ferritin concentration is elevated (850–4000 ng/mL; normal 30–200), the serum
iron concentration is decreased (<45 g/dL; normal 60–180), and most patients have a mild anemia
(178]. Autopsy findings reveal iron in the pancreas with accumulation in the islets of Langerhans in
association with a selective loss of insulin-producing cells [181]. All patients exhibit abnormal glucose
metabolism and most develop insulin-dependent diabetes. The presence of iron overload in the liver,
insulin-dependent diabetes mellitus, and hyperferritinemia can mimic hemochromatosis, and in fact
in at least one occasion had led to its misdiagnosis [182]. The iron content in the liver is greater than
in the brain [183].
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The most significant pathology, however, involves progressive degeneration of the basal ganglia
due to iron deposition. Patients present with dysarthria, dystonia, and dementia in the fourth decade
of life. Brain tissue at autopsy shows abundant iron deposition, more prominent in astrocytes than
in neurons, with neuronal loss [181, 183]. The main site of iron accumulation is the globus pallidus,
followed by the putamen > thalami > cerebellar cortex > hippocampus [183]. There is marked loss of
Purkinje cells in the cerebellum [183]. The characteristic features are abnormal, deformed astrocytes
and globular structures [184]. Astrocytes in the basal ganglia are enlarged, up to 50 m in size, with
abundant cytoplasm and prominent nuclei, some with lobulated nuclei or multinucleated [183–185].
These are similar to Alzheimer type 1 astrocytes [185]. Globular structures are grumose or foamy
spheroid bodies, 10 to 60 m in diameter, seen mainly in the basal ganglia and superficial layers of
the frontal cortex [183–185]. These globular structures stain strongly with anti-GFAP antibodies, but
only faintly with antibodies for neuronal markers such as neurofilment and synaptophysin [185]. This
attests to their glial origin, and distinguishes them from spheroids, which are axonal swellings from
neurons [183]. Ultrastructurally, many electron-dense bodies can be seen inside the globular structures
[183]. With increased duration of the disease, the aforementioned pathologic processes extend from the
basal ganglia into the cerebral cortex [186]. Ophthalmologic examination reveals iron deposition and
photoreceptor loss in the peripheral regions of the retina. Involvement of the central nervous system
indicates that ceruloplasmin plays an essential role in brain iron metabolism.
Although all patients with aceruloplasminemia have low serum copper (<10 g/dL) owing to the
absence of this protein in the serum, copper metabolism in such patients remains normal [93]. Patients
with aceruloplasminemia have normal liver histology on biopsy with no evidence of hepatic copper
accumulation [181].
Iron chelators such as desferrioxamine and deferasirox reduce body iron stores and can ameliorate
the neurologic symptoms of patients with aceruloplasminemia if initiated early enough in the course
of the disease [187]. In one case, however, only hepatic and not brain iron was chelated [188].
3. Iron homeostasis
Humans absorb iron through the gastrointestinal tract and excrete iron only through the bile and
urine. The total body iron pool ranges from 2 to 6 g in normal adults; about 0.5 g is stored in the
liver, 98% of which is in hepatocytes. The normal flux is 1 mg/day for men and 1.5–2.0 for women
[189]. Iron absorption requires transporters at the apical and basolateral membranes of gastrointestinal
mucosal cells. The basolateral transporter, ferroportin, can bind a protein called hepcidin that inactivates
ferroportin and causes iron to remain within mucosal cells, which eventually slough. Hepcidin, a
hormone produced in the liver in response to high transferrrin saturation [102], also inhibits iron
release from macrophages. Iron overload occurs whenever net absorption of iron is excessive.
3.1. Hereditary hemochromatosis
Hemochromatosis is the excessive accumulation of body iron, most of which is deposited in the
parenchymal cells of various organs, particularly liver and pancreas [190]. In hemochromatosis, total
iron accumulation may exceed 50 g. Iron accumulation is lifelong; symptoms usually first appear in
the fifth to sixth decades of life.
Hereditary hemochromatosis is the most common autosomal recessive genetic disease in the Cau-
casian population [191–193]. With an incidence of 1 in 200 live births, it affects 1.5 million people
in the United States, although most are asymptomatic. Biallelic mutations in one of five different
genes cause hemochromatosis: HFE; HJV and HAMP, both causative of juvenile hemochromatosis
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-or hemochromatosis type 2- leading to severe iron overload before the age of 30 years); TFR2, causing
hemochromatosis type 3; and FTH1, causing hemochromatosis type 5, or Japanese iron overload. All
are autosomal recessive conditions, with the exception of hemochromatosis type 5, which is dominant.
Their gene products function in the signaling pathway that produces hepcidin in hepatocytes. Lack
of hepcidin allows for unregulated gastrointestinal absorption of iron. The primary hemochromato-
sis gene, HFE, is located on the short arm of chromosome 6, close to the HLA gene locus [194].
Two mutations, C282Y and H63D (new nomenclature: p.Cys282Tyr and p.His63Asp), account for the
vast majority of hemochromatosis [191–193]. Affected patients are either homozygous for C282Y or
compound heterozygous for C282Y and H63D. Hemochromatosis can also be caused by ferroportin
resistance to hepcidin (see below) [195]. Iron overload is also seen in congenital atransferrinemia due
to mutations in the TF gene, characterized by early-onset: 1) severe microcytic, hypochromic anemia
refractory to iron therapy; 2) liver iron overload with significant iron deposition in both hepatocytes
and Kupffer cells; 3) absent transferrin, leading to a decreased -globulin fraction on serum protein
electrophoresis [196]. Finally, yet another hereditary condition that can lead to early-onset severe hep-
atic iron overload with microcytic, hypochromic anemia is caused by mutations in the gene SLC11A2,
encoding for the divalent metal transporter DMT1 [197, 198].
3.1.1. Clinical characteristics
In hemochromatosis patients, excessive intestinal iron absorption leads to net iron accumulation of
0.5 to 1.0 g per year [191]. Symptoms typically develop after 20 g of storage iron have accumulated.
Males predominate (5–7 : 1) with slightly earlier clinical presentation, partly because physiologic iron
loss (menstruation, pregnancy) delays iron accumulation in women. The proposed mechanisms for
iron toxicity is through lipid peroxidation via iron-catalyzed free radical reaction (Fenton reaction),
iron stimulation, and collagen formation. Direct interaction of iron with DNA leads to alterations in
hepatic morphology and predisposes to hepatocellular carcinoma. It is reversible in cells not injured
by iron accumulation, and removal of excess iron during therapy promotes recovery of tissue function.
Patients with hemochromatosis manifest hepatomegaly, abdominal pain, skin pigmentation (par-
ticularly in sun-exposed areas), deranged glucose homeostasis or frank diabetes mellitus, cardiac
dysfunction (arrhythmias, cardiomyopathy), and atypical arthritis [193, 199] (Table 5). In some
patients, the presenting complaint is hypogonadism, with amenorrhea in the female and loss of libido
and impotence in the male. The classic triad of pigment cirrhosis with hepatomegaly, skin pigmenta-
tion, and diabetes mellitus does not always develop. Death may result from cirrhosis or cardiac disease.
Hemochromatosis patients carry a risk for hepatocellular carcinoma that is 200-fold greater than that of
the general population [200]. Depletion of iron, and even reversal of cirrhosis, does not totally prevent
the occurrence of this fatal neoplasm [200].
The severity of myocardial involvement varies widely and does not correlate with the severity
in other organs. Cardiac involvement, whose severity is proportional to the quantity of myocardial
iron deposition, leads to a mixed dilated-restrictive cardiomyopathy, with both systolic and diastolic
dysfunction [201]. The possibility of cardiac hemochromatosis should be considered in any patient
with unexplained heart failure.
3.1.2. Diagnosis
Screening for HHC is accomplished by measuring serum iron, total iron-binding capacity, and
ferritin levels, followed by liver biopsy, if indicated. Most important for identification of patients with
asymptomatic HHC is screening of family members. Heterozygotes for HHC accumulate excessive
iron, but not to the degree required to cause significant tissue damage. A diagnosis of hemochromatosis
can be suspected based upon a serum ferritin concentration of more than 400 g per liter or a transferrin
saturation of more than 45%. The serum ferritin concentration correlates well with the level of hepatic
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Table 5
Hereditary hemochromatosis
Homozygote frequency 1 in 200
Carrier frequency (N. Europeans) Approx. 1 in 10
Disease expression: males to females Approx. 5 : 1 (juvenile cases show equal sex ratio)
Other modifying factors Alcohol (approx. 80% of established cases) underlying red blood cell disorders,
such as spherocytosis, -thalassemia
Age of onset >40-year-long presymptomatic period
Clinical features Nonspecific fatigue; asthenia; joint pains; loss of libido and impotence; diabetes
mellitus; liver enlargement; increased skin pigmentation; cardiac disease;
increased risk of hepatocellular carcinoma.
Treatment Phlebotomy and/or iron chelators.
Prognosis Untreated disease shortens life; treatment before cirrhosis develops compatible
with normal life expectancy.
Fig. 12. Hereditary hemochromatosis. Gross appearance of micronodular cirrhotic liver.
iron stores; the transferrin saturation test is believed to be sufficient as a screening test. A bone marrow
biopsy is not helpful in diagnosis since the bone marrow does not store iron in HHC. Hepatic iron
content can be estimated non-invasively through magnetic resonance imaging [202, 203].
3.1.3. Pathology
Although iron overload occurs via excessive intestinal absorption, iron accumulates as ferritin and
hemosiderin in the parenchymal tissues of the body and in the linings of joints, without significant depo-
sition in the bone marrow. In the liver [204], iron becomes evident first as golden yellow hemosiderin
granules in the cytoplasm of periportal hepatocytes, particularly in lysosomes (siderosomes) within
the pericanalicular cytoplasm [205]. With increasing iron load, there is progressive involvement of the
lobule –extending from zone 1 toward zone 3- and bile duct epithelium. Kupffer cell pigmentation
is less marked, in distinction from secondary causes of iron overload such as hemoglobinopathies
or blood transfusions [206]. Because iron is a direct hepatotoxin, inflammation is characteristically
absent. At this stage, the liver is typically slightly larger than normal, dense, and brown. Fibrous septa
develop slowly, leading ultimately to a micronodular pattern of cirrhosis (Fig. 12) [41]. The overall
reduction in liver size is rarely marked.
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Fig. 13. Microscopic appearance of liver in hereditary hemochromatosis showing iron in hepatocytes. Prussian blue stain.
Fig. 14. Microscopic appearance of the pancreas in hereditary hemochromatosis showing iron pigment in pancreatic acinar
and islet cells. Prussian blue stain.
The Prussian blue reaction (potassium ferrocyanide and hydrochloric acid) is used to stain the
hemosiderin granules blue-black (Fig. 13). Because this stain does not stain ferritin-bound iron, bio-
chemical determination of hepatic iron concentration in unfixed tissue is the standard for quantitating
iron content. In normal individuals, it is less than 1000 g iron/g dry weight; hepatic iron concentra-
tions in excess of 22,000 g/g dry weight (300 mol/g) carry a risk for the development of fibrosis
and cirrhosis [207].
The pancreas becomes intensely pigmented (Fig. 15), has diffuse interstitial fibrosis, and may exhibit
some parenchymal atrophy. Hemosiderin is found in both the acinar and the islet cells and sometimes
in the interstitial fibrous stroma. The intensity of iron staining in the pancreatic islets correlates with
the occurrence and severity of the diabetes.
The heart is often enlarged and has hemosiderin granules within the myocardial fibers, inducing
a striking brown coloration to the myocardium (Fig. 15). A delicate interstitial fibrosis may appear.
Myocardial iron deposition (Fig. 16) results in an increase in the thickness of the left ventricular
wall and reduces left ventricular compliance, with an eventual decline in the left ventricular systolic
function and ventricular dilation. Myocardial iron deposits are sarcoplasmic and are most common
in the subepicardial region, followed by the subendocardial region; they are least common in the
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Fig. 15. Gross appearance of the heart in hereditary hemochromatosis showing iron pigmentation.
Fig. 16. Microscopic section of the heart in hereditary hemochromatosis showing iron pigment in the myocardial cells.
midmyocardial wall. Iron deposition is more extensive in the ventricles than in the atria, and the
cardiac conduction system is frequently involved.
The skin usually has increased pigmentation, mainly owing to increased epithelial melanin (seen also
with other forms of cirrhosis). A distinctive metallo-slate-gray pigmentation is related to accumulation
of hemosiderin in dermal macrophages and fibroblasts.
With hemosiderin deposition in the joint synovium, an acute synovitis may develop. Excessive
deposition of calcium pyrophosphate damages the articular cartilage, producing disabling arthritis
referred to as pseudogout.
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The testes may be small and atrophic but are not usually significantly pigmented. It is thought that the
atrophy is secondary to a derangement in the hypothalamic-pituitary axis. Other parenchymal organs,
particularly endocrine (e.g., adrenals, thyroid), may also accumulate iron.
3.1.4. Treatment
The treatment of choice for hemochromatosis is regular phlebotomy, although iron chelators can
also be used. The rate of phlebotomy is usually 3-4 units per year after the initial removal of 500 mL
of blood once or twice each week upon diagnosis [191]. Treatment goal is a serum ferritin of around
50 g/L, since lower levels -of around 20 g/L- are associated with a rebound increase in nonheme
iron absorption [208]. The serum ferritin concentration usually becomes normal before the transferrin
saturation, and in fact transferrin saturation can still remain elevated under conditions of iron defi-
ciency. Thus, the best marker for monitoring goals of therapy is serum transferrin [208]. Patients with
hemochromatosis diagnosed in the subclinical, precirrhotic stage and treated by regular phlebotomy
have a normal life expectancy [200].
3.1.5. Ferroportin disease
SLC40A1 encodes ferroportin, the only known mammalian iron exporter, present in macrophages
and in the basolateral membrane of hepatocytes and enterocytes. Loss-of-function mutations lead
to classical–or type A–ferroportin disease, characterized by iron accumulation predominantly in
macrophages, with increased ferritin but low-to-normal transferrin saturation until late in the disease.
Both features distinguish it from hemochromatosis, although ferroportin disease has also been called
hemochromatosis 4. However, non-classical –or type B- ferroportin disease, caused by mutations
leading to hepcidin resistance, is associated with iron overload within hepatocytes and increased trans-
ferrin saturation and ferritin, thus mimicking HHC [209]. However, ferroportin disease is inherited in
an autosomal dominant manner.
4. Zinc homeostasis
An average-sized adult male has 1.4 to 2.3 g of zinc, about 40% of the total body iron content, and
10–20 times that of copper. Mean consumption of zinc for an adult is about 10–15 mg daily, absorbed
predominantly in the duodenum and proximal jejunum, and excreted mainly in the feces [210]. Zinc is
a cofactor for several enzymes, including ornithine transcarbamylase, alkaline phosphatase, carbonic
anhydrase, superoxide dismutase, DNA and RNA polymerases, lactate dehydrogenase, alcohol dehy-
drogenase, insulin-degrading enzyme, matrix metalloproteinases, and N-acyl D-aspartate acylase. All
major metabolic pathways are regulated by zinc metalloenzymes. The functions of these enzymes
include catalytic, structural, and regulatory roles [211].
4.1. Acrodermatitis enteropathica
This disturbance of zinc homeostasis results from a partial block in the intestinal absorption of zinc,
resulting in a severe zinc deficiency state with impaired function of zinc metalloenzymes. It is inherited
in an autosomal recessive fashion, and the responsible gene is SLC39A4, encoding for ZIP4 [212–214],
a zinc transport protein.
4.1.1. Clinical characteristics
The most dramatic clinical feature of acrodermatitis enteropathica is a skin rash that has a characteris-
tic symmetrical, circumoral, retroauricular, and acral distribution. The skin lesions are erythematous in
the acute stages, then vesicobullous and pustular, and later hyperkeratotic. Secondary infection is com-
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mon, usually with candida or staphylococci, which may lead to misdiagnosis. Mucosal lesions include
gingivitis, stomatitis, and glossitis. Symptoms are usually present in infancy. The onset is delayed in
breast-fed infants until after weaning, whereas babies fed infant formula develop the disorder as early
as the first 2–4 weeks of life. During early infancy, frequent passage of watery stools, anorexia, and
failure to thrive often precede the skin lesions. Total alopecia occurs frequently. Nail deformities and
ophthalmologic problems including blepharitis, conjunctivitis, photophobia, and impaired dark adap-
tion may occur. Mood changes, irritability, lethargy, or depressed mental status are also early features
of zinc deficiency, as are recurrent infections. Symptoms are aggravated during infections and physio-
logic stress, at growth spurts in early childhood, and in puberty. After puberty, men are less vulnerable
to zinc deficiency than women. One-third of pregnancies of untreated patients result in spontaneous
abortion or in congenital defects of the skeletal or central nervous system [215]. Fluctuations occur,
but the clinical course is usually progressive without zinc therapy.
4.1.2. Diagnosis
The diagnosis in patients with the characteristic clinical picture can be suspected if markedly reduced
plasma zinc values are found. In most patients, plasma zinc is reduced to 3 to 6 mol/L (normal range,
9 to 20 mol/L). The diagnosis is established if, after successful zinc therapy and clinical remission,
a withdrawal of zinc leads to a relapse.
Blood samples for zinc analysis should be taken in the morning in the fasting state and the patient
should preferably be without infection. By analyzing plasma zinc, the diagnosis of AE can never be
proven beyond doubt. In some plasma, zinc may be normal because of zinc released from catabolized
tissues. On the other hand, plasma zinc may be low because of acquired zinc deficiency or redistribution
of zinc to other body pools during stress and infection. Neutrophils, lymphocytes, or red blood cells are
unsuitable for zinc determination. Usually urinary zinc excretion is decreased if plasma zinc is low, and
sometimes plasma copper is at the upper range of normal. In general, plasma alkaline phosphatase par-
allels plasma zinc during severe zinc deficiency. Hair zinc is unreliable in acrodermatitis enteropathica
because hair growth is often impaired. Elevated blood ammonia (due to ornithine transcarbamylase
deficiency), hypobetalipoproteinemia, and an altered fatty acid pattern also occur. In many patients,
impaired immune responses are associated with zinc deficiency states, pointing to depressed humoral
and cell-mediated immunity.
4.1.3. Pathology
Skin biopsy shows epidermal vacuolation with clear epidermal cells (Fig. 17) and parakeratosis.
The dermis may show a sparse lymphohistiocytic inflammatory infiltrate. Ultrastructurally, Paneth
cells of the intestinal mucosa show inclusions, as well as pleomorphic granules, sometimes becoming
confluent, giving rise to giant granules [216–218]. Some enterocytes contain large lysosomal inclusion
bodies [216]. These changes regress with therapy.
4.1.4. Treatment
The bioavailability of zinc from human milk is higher than from other dietary sources, so breast-fed
babies may not develop symptoms until breast-feeding is discontinued. Zinc supplementation results
in the disappearance of skin lesions within a week (Fig. 18), as plasma and urinary excretion of zinc,
as well as serum alkaline phosphatase values, increase to normal levels. The usual therapeutic dose is
between 30 and 50 mg Zn/day (10–30 mol Zn/kg/day). Zinc is not very toxic, thus higher amounts
of 50 to 200 mg do not cause side effects. Plasma copper should be monitored to avoid hypocupremia.
The zinc salts used are gluconate, acetate, and, more often, sulfate, administered in 3 divided doses
daily if gastric problems occur. In many patients the total dose per day remains constant during their
entire childhood.
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Fig. 17. Microscopic appearance of skin in acrodermatitis enteropathica showing epidermal vacuolar degeneration.
Fig. 18. Acrodermatitis enteropathica showing skin rash. (A) Before treatment. (B) After zinc treatment. (Courtesy of Dr.
Bernard Cohen.)
4.2. Transient neonatal zinc deficiency
SLC30A2 encodes ZnT2, a zinc transporter in mammary epithelial cells. Transient neonatal zinc
deficiency is caused by maternal heterozygous mutations in SLC30A2, leading to low maternal milk
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zinc concentrations. Infants have a clinical phenotype similar to acrodermatitis enteropathica while
receiving breastmilk, but the symptoms resolve after weaning [217–219].
4.3. Spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS)
This disorder is caused by biallelic mutations in SLC39A13, which encodes the zinc transporter
ZIP13. It is characterized by EDS-like features and radiological findings of a skeletal dysplasia [220].
The EDS-like features include hyperelastic, thin, translucent skin with easy bruising, atrophic scars,
wrinkled palms, flat feet, joint hypermobility with subsequent contractures of small joints, down-
slanting palpebral fissures, bluish sclerae and protuberant eyes. Short stature is a common feature.
Radiological findings include platyspondyly, osteopenia, irregular endplates of the vertebral bodies,
metaphyseal widening and epiphyseal flattening [220]. The urinary deoxypyridinoline-to-pyridinoline
ratio is about 5 times the normal mean, but 6 times less than in the kyphoscoliotic form of EDS. Serum
zinc levels are normal, but the intracellular distribution of zinc is abnormal, leading to abnormal nuclear
translocation of SMADs, which in turn alters TGF- and BMP signaling in collagen-producing cells
[221]. Skin biopsies evaluated by electron microscopy revealed normal elastin amount and structure,
and normal shape and diameter of the collagen fibrils [220].
4.4. Birk-Landau-Perez syndrome
This novel condition is associated with biallelic mutations in SLC30A9, encoding ZnT9 [222].
Clinically, it manifests as a cerebro-renal syndrome with early-onset intellectual disability and tubu-
lointerstitial nephropathy. Patients exhibit normal development for the first 1-2 years of life, but
subsequently show progressive neurodeterioration. Brain MRI does not show any specific structural
anomalies. ZnT9 is located in the endoplasmic reticulum, and its deficiency leads to disrupted zinc
homeostasis, with decreased cytosolic zinc concentrations [222].
5. Manganese homeostasis
The total body content of manganese in an adult human is 12–20 mg. The daily turnover of manganese
is estimated at 20 g, while the dietary intake varies from 2–22 mg/day, with 2–10% being absorbed
throughout the length of the small intestine [223]. Thus, the dietary intake of manganese greatly exceeds
its daily need. There is an inverse correlation between iron intake and manganese absorption, as they
both compete for the same divalent metal transporter, DMT1 [224]. Once absorbed, excess manganese
is excreted by the liver into the bile [224]. Examples of manganese-binding enzymes can be found in
Table 6.
5.1. Hypermanganesemia with dystonia, polycythemia and cirrhosis (HMDPC)
This disorder, also known as hypermanganesemia with dystonia type 1, is caused by biallelic muta-
tions in SLC30A10 [225, 226], which encodes for a manganese exporter [227] mainly expressed in the
small intestine, liver and brain [228]. The disease has been described in 20 individuals from 10 families,
and is characterized by childhood-onset dystonia or adult-onset parkinsonism, chronic liver disease,
polycythemia, and hypermanganesemia with levels often above 2,000 nmol/L (reference: <320 nmol/L)
[229]. Four-limb dystonia leads to a characteristic “cock-walk” gait [230]. Liver disease is present in
most patients, with hepatomegaly, increased transaminases and indirect hyperbilirubinemia. Mean
hemoglobin concentration is 18.6 mg/dL, and the polycythemia is thought to be related to induction of
erythropoietin gene expression by manganese [229]. Brain MRI reveals T1-weighted hyperintensity
of the basal ganglia. There is depletion of iron stores with low serum ferritin and iron levels. Chelation




Glycosyl tranferases Glycosaminoglycan synthesis
Prolidase Collagen recycling
Arginase Urea synthesis
Glutamine synthetase Glutamine synthesis
Superoxide dismutase (SOD)∗ Antioxidant
Pyruvate carboxylase Gluconeogenesis
Phosphoenolpyruvate carboxykinase
Isocitrate dehydrogenase Krebs cycle
∗The mitochondrial SOD uses manganese as a cofactor, while the cytoplasmic SOD uses
copper and zinc.
therapy with intravenous disodium calcium edetate infusion leads to amelioration of symptoms and
decrease in manganese levels. Iron supplementation is also helpful, as it competes for the same trans-
porter as manganese. Mutations causing this disease are known to alter intracellular trafficking and
efflux activity of the exporter [227]. Liver pathology in one patient showed micronodular cirrhosis,
scattered macrovesicular steatosis, and brown-orange pigment that stains with rhodanine within the
cytoplasm of hepatocytes [231]. The patient also showed hypertrophic cardiomyopathy with rhodanine-
positive aggregates in rare cardiomyocytes. Gross brain pathology revealed yellow-gray discoloration
of the basal ganglia, predominantly in the globus pallidus. Microscopically, the basal ganglia showed
severe neuronal loss with reactive astrocytosis. Rhodanine-positive pigment was seen in the remaining
neurons, astrocytes, neuropil and scattered macrophages in the globus pallidus. The substantia nigra had
poorly pigmented neurons, although regular in number. Ultrastructurally, membrane-bound, electron-
dense multigranular deposits could be found in the remaining pallidal neurons and in hepatocytes
[231].
5.2. Hypermanganesemia with dystonia type 2
This new syndrome is associated with biallelic mutations in SLC39A14, encoding ZIP14 [232].
Patients typically present between 6 months and 3 years of life with delay or loss of motor milestones,
followed by dystonia, spasticity, and Parkinsonism [233]. Brain MRI reveals T1-weighted hyperin-
tensities of the basal ganglia with sparing of the thalami, and of the white matter of the cerebellum,
spinal cord, and dorsal pons, with ventral pons sparing [233]. There is decreased visceral uptake of
manganese, so the liver is spared, but there is consequent elevation of whole blood manganese concen-
trations, leading to brain deposition. Chelation therapy with disodium calcium edetate leads to dramatic
clinical improvement. Neuropathology at autopsy in one individual revealed marked neuronal loss and
gliosis in the globus pallidus and dentate nucleus of the cerebellum, the latter also with a few rounded
eosinophilic spheroid structures. A patchy vacuolated myelinopathy was observed in the white matter
of the cerebrum and cerebellum. Iron deposition, axonal spheroids, tau or alpha-synuclein pathology
were not observed [232, 233].
5.3. SLC39A8 deficiency
A deficiency of this transporter leads to variable short stature and neurologic symptoms, such as
intellectual disability, infantile spasms, hypotonia and cerebellar atrophy [234, 235]. There is a founder
mutation in the Hutterite population [234]. Aside from cerebral and cerebellar atrophy, the brain
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MRI can also reveal restricted diffusion and T2-weighted hyperintensities of the basal ganglia [236].
Variably low concentrations of manganese and zinc are found in blood, with elevated concentrations
in the urine, indicating renal wasting [234]. The low availability of manganese leads to a deficient
activity of manganese-dependent enzymes, such as for example beta-1,4-galactosyltransferase. The
deficiency of the latter leads to a type II glycosylation pattern on transferrin analysis; supplementation
with galactose and uridine led a normalization of glycosylation [235]. More recently, treatment with
manganese supplementation was attempted in two patients, with improvement of neurologic symptoms,
although it should be noted that patients under this treatment should be carefully monitored for findings
of manganism [237].
6. Selenium homeostasis
The total body content of selenium for an adult living in the US varies from 13.0 to 20.3 mg [238],
although this value is lower in people living in countries with low selenium intake. Selenium is mainly
found in foods in its organic form -selenomethionine in plant sources, selenocysteine in animal sources-
while the inorganic forms of selenium –selenite and selenite- are mainly found in dietary supplements.
More than 80% of the ingested selenium is absorbed through the small intestines. There are 25 human
selenoproteins, including 5 forms of glutathione peroxidase, 3 forms of thioredoxin reductase, and 3
deiodinases, the latter participating in thyroid hormone metabolism [239, 240]. Selenoproteins contain
selenocysteine, the 21st proteinogenic amino acid. In selenocysteine, the oxygen molecule from serine
or the sulfur molecule from cysteine is replaced by selenium. Selenocysteine lacks its own tRNA
synthetase, and is instead synthesized on its cognate tRNA, called tRNA[Ser]Sec. tRNA[Ser]Sec is first
loaded with serine by seryl-tRNA synthetase (SARS). The newly-formed ser-tRNA[Ser]Sec is then
phosphorylated by O-phosphoseryl-tRNA kinase (PSTK). The phosphate group from the resulting O-
phosphoseryl-tRNA is then replaced by selenium –using selenophosphate as a donor- by the action of
the O-phosphoseryl-tRNA:selenocysteinyl-tRNA synthase (SepSecS) [241]. A selenocysteinyl-tRNA-
specific eukaryotic elongation factor (EEFSEC) then carries the Sec- tRNA[Ser]Sec to the ribosome
[242].
Selenocysteine is not encoded by an independent codon, but rather by the UGA stop codon. The UGA
codon is interpreted as a Sec codon, as opposed to a stop codon, by the presence of a stem-loop structure
-the Sec-insertion sequence (SECIS) element- in the 3’-untranslated region of the selenoprotein mRNA.
SECIS-binding protein 2 (SBP2) binds to the SECIS element and recruits the Sec-specific elongation
factor carrying the Sec- tRNA[Ser]Sec to the mRNA of the selenoprotein [242].
6.1. SBP2 deficiency
The disease is caused by biallelic mutations in SECISBP2, encoding SBP2. In 10 patients from 8
different families, all had abnormal thyroid metabolism, with elevated T4 and rT3, high/normal TSH,
and low T3 levels. Thyroid testing was performed due to delayed growth and delayed bone age [243].
Developmental motor and/or speech delays were seen in 5 patients, sensorineural hearing loss in 4, and
progressive congenital myopathy in 2 [243]. Serum selenium concentration is low, indicating a global
selenoprotein synthesis deficiency. Thyroid function abnormalities do not normalize after organic or
inorganic selenium supplementation [244]. Muscle biopsy in one patient showed marked type 1 fiber
predominance, with occasional minicores [245].
6.2. Progressive cerebello-cerebral atrophy
Caused by biallelic mutations in SEPSECS, the disease is characterized by profound intellectual
disability, progressive postnatal microcephaly and spasticity, progressive atrophy of the cerebrum and
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cerebellum, and variable myoclonic or generalized tonic-clonic seizures [246, 247]. Neuropathology
reveals subtotal laminar necrosis of the neocortex, mainly involving the parietooccipital regions, with
relative sparing of the hippocampus [248]. There is severe olivopontocerebellar atrophy, involving the
basis pontis, inferior olives, tegmentum of the medulla oblongata, and cerebellar cortex, the latter with
thin molecular and granular layers, and subtotal loss of Purkinje cells [248]. There is also spinal cord
atrophy, predominantly involving the posterior columns [248].
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[220] C. Giunta, N.H. Elçioglu, B. Albrecht, G. Eich, C. Chambaz, A.R. Janecke, et al., Spondylocheiro dysplastic form
of the Ehlers-Danlos syndrome–an autosomal-recessive entity caused by mutations in the zinc transporter gene
SLC39A13, Am J Hum Genet 82(6) (2008), 1290–1305.
[221] T. Fukada, N. Civic, T. Furuichi, S. Shimoda, K. Mishima, H. Higashiyama, et al., The zinc transporter
SLC39A13/ZIP13 is required for connective tissue development; its involvement in BMP/TGF-beta signaling path-
ways, PLoS One 3(11) (2008), e3642.
[222] Y. Perez, Z. Shorer, K. Liani-Leibson, P. Chabosseau, R. Kadir, M. Volodarsky, et al., SLC30A9 mutation affecting
intracellular zinc homeostasis causes a novel cerebro-renal syndrome, Brain J Neurol 140(4) (2017), 928–939.
[223] M. Brandt and V.L. Schramm, Chapter 1 - Mammalian manganese metabolism and manganese uptake and distribution
in rat hepatocytes. In: Wedler VLSC, editor. Manganese in Metabolism and Enzyme Function [Internet]. Academic
Press; 1986. pp. 3–16. Available from: http://www.sciencedirect.com/science/article/pii/B9780126290509500053
[224] K. Tuschl, P.B. Mills and P.T. Clayton, Manganese and the brain, Int Rev Neurobiol 110 (2013), 277–312.
[225] K. Tuschl, P.T. Clayton, S.M. Gospe, S. Gulab, S. Ibrahim, P. Singhi, et al., Syndrome of hepatic cirrhosis, dystonia,
polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man, Am J
Hum Genet 90(3) (2012), 457–466.
[226] M. Quadri, A. Federico, T. Zhao, G.J. Breedveld, C. Battisti, C. Delnooz, et al., Mutations in SLC30A10 cause
parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease, Am J Hum Genet
90(3) (2012), 467–477.
[227] D. Leyva-Illades, P. Chen, C.E. Zogzas, S. Hutchens, J.M. Mercado, C.D. Swaim, et al., SLC30A10 Is a Cell Surface-
Localized Manganese Efflux Transporter, and Parkinsonism-Causing Mutations Block Its Intracellular Trafficking
and Efflux Activity, J Neurosci 34(42) (2014), 14079–14095.
[228] H.J. Bosomworth, J.K. Thornton, L.J. Coneyworth, D. Ford and R.A. Valentine, Efflux function, tissue-specific
expression and intracellular trafficking of the Zn transporter ZnT10 indicate roles in adult Zn homeostasis,
Metallomics 4(8) (2012), 771–779.
[229] K. Tuschl, P.T. Clayton, S.M. Gospe and P.B. Mills, Dystonia/Parkinsonism, Hypermanganesemia, Polycythemia,
and Chronic Liver Disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors.
GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2015 Aug 29]. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK100241/
[230] M.A. Avelino, E.F. Fusão, J.L. Pedroso, J.H. Arita, R.T. Ribeiro, R.S. Pinho, et al., Inherited manganism: The
“cock-walk” gait and typical neuroimaging features, J Neurol Sci 341(1-2) (2014), 150–152.
[231] M. Lechpammer, M.S. Clegg, Z. Muzar, P.A. Huebner, L-W Jin and S.M. Gospe, Pathology of inherited manganese
transporter deficiency, Ann Neurol 75(4) (2014), 608–612.
[232] K. Tuschl, E. Meyer, L.E. Valdivia, N. Zhao, C. Dadswell, A. Abdul-Sada, et al., Mutations in SLC39A14 disrupt
manganese homeostasis and cause childhood-onset parkinsonism-dystonia, Nat Commun 7 (2016), 11601.
[233] K. Tuschl, A. Gregory, E. Meyer, P.T. Clayton, S.J. Hayflick, P.B. Mills, et al., SLC39A14 Deficiency. In: Pagon
RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®) [Internet].
Seattle (WA): University of Washington, Seattle; 1993 [cited 2017 Sep 25]. Available from: http://www.ncbi.
nlm.nih.gov/books/NBK431123/
[234] K.M. Boycott, C.L. Beaulieu, K.D. Kernohan, O.H. Gebril, A. Mhanni, A.E. Chudley, et al., Autosomal-Recessive
Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter
Gene SLC39A8, Am J Hum Genet 97(6) (2015), 886–893.
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